Project Details
Description
PROJECT SUMMARY/ABSTRACT
This application is a request for funding of a research program focused on understanding the factors associated with waning immune response to mumps vaccine. Waning immunity to mumps is a public health concern
and a major obstacle in the control and elimination of mumps disease. Outbreaks in the US and Europe primarily occur among highly vaccinated populations in their late teens and early twenties. These outbreaks are
primarily due to the waning of mumps vaccine-induced immunity. Waning immunity to mumps is defined by
decrease in antibody titer over time, decreased vaccine effectiveness in older subjects, and increased susceptibility to disease as time since vaccination increases; however, little information is available on the qualitative
characteristics of mumps-specific memory B cells, and even less data is available regarding long-term T cell
responses to mumps. Our goal is to study the first factor (decrease in immune responses over time). The establishment of long-lasting immunity to mumps is likely to be controlled by multiple immunologic pathways,
networks, and cell types acting in a coordinated and interactive manner. We propose to characterize B cell and
CD4+ T cell responses to a 3rd dose of MMR. We will then examine how baseline characteristics (e.g., prior Ab
response and sex) and genetic factors (mRNA and miRNA) influence those immune responses using a systems-biology approach and mediation analysis. In order to accomplish this objective, we propose the following
Specific Aims: 1) To conduct a systems biology study of early humoral (B cell) immune responses; 2) To conduct a systems biology study of early CD4+ T helper responses; and 3) To characterize interrelationships between T helper cell and humoral immune responses. These aims will allow us to comprehensively assess
how— and to what degree—baseline immunity, the early primary response to a 3rd dose of MMR, and the establishment of memory and return to homeostasis after MMR vaccination contribute to the observed clinical
waning of mumps immunity. In turn, this knowledge can be utilized to inform mechanistic studies of mumps
vaccine-induced immune persistence, develop more effective mumps vaccines and adjuvants in the future, and
to identify possible early biomarkers to detect those at greatest risk of waning protection against mumps.
Status | Finished |
---|---|
Effective start/end date | 6/15/18 → 5/31/23 |
Funding
- National Institute of Allergy and Infectious Diseases: $783,307.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.